Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatectomy | 11 | 2021 | 104 | 2.760 |
Why?
|
| Robotics | 9 | 2013 | 86 | 2.430 |
Why?
|
| Laparoscopy | 19 | 2020 | 492 | 2.100 |
Why?
|
| Prostatic Neoplasms | 10 | 2022 | 501 | 2.040 |
Why?
|
| Prostate | 5 | 2022 | 124 | 1.370 |
Why?
|
| Nephrectomy | 8 | 2012 | 93 | 1.210 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2018 | 109 | 0.970 |
Why?
|
| Kidney Neoplasms | 7 | 2023 | 173 | 0.910 |
Why?
|
| Urologic Surgical Procedures | 6 | 2020 | 46 | 0.800 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 84 | 0.780 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 93 | 0.690 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 6 | 0.660 |
Why?
|
| Robotic Surgical Procedures | 4 | 2020 | 172 | 0.660 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 5 | 0.640 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 20 | 0.640 |
Why?
|
| Postoperative Complications | 6 | 2021 | 1335 | 0.630 |
Why?
|
| Ureteral Obstruction | 4 | 2019 | 27 | 0.600 |
Why?
|
| Hemostasis, Surgical | 5 | 2012 | 22 | 0.560 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2023 | 113 | 0.560 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 462 | 0.520 |
Why?
|
| Ureter | 3 | 2019 | 37 | 0.510 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 2020 | 49 | 0.510 |
Why?
|
| Poloxamer | 3 | 2012 | 16 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 264 | 0.480 |
Why?
|
| Blood Loss, Surgical | 3 | 2012 | 65 | 0.470 |
Why?
|
| Urology | 3 | 2020 | 46 | 0.470 |
Why?
|
| Lymphocele | 1 | 2015 | 5 | 0.450 |
Why?
|
| Peritoneum | 1 | 2015 | 31 | 0.450 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 52 | 0.440 |
Why?
|
| Surgical Flaps | 1 | 2015 | 117 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 2252 | 0.400 |
Why?
|
| Urethra | 3 | 2014 | 77 | 0.390 |
Why?
|
| Male | 30 | 2022 | 31285 | 0.380 |
Why?
|
| Cystectomy | 4 | 2018 | 35 | 0.380 |
Why?
|
| Replantation | 1 | 2011 | 11 | 0.350 |
Why?
|
| Sutures | 1 | 2012 | 40 | 0.350 |
Why?
|
| Urinary Bladder | 2 | 2009 | 48 | 0.350 |
Why?
|
| Humans | 41 | 2023 | 65635 | 0.340 |
Why?
|
| Renal Artery | 3 | 2011 | 36 | 0.340 |
Why?
|
| Middle Aged | 18 | 2021 | 18434 | 0.330 |
Why?
|
| Treatment Outcome | 11 | 2020 | 5818 | 0.290 |
Why?
|
| Biopsy | 3 | 2021 | 460 | 0.280 |
Why?
|
| Triage | 2 | 2020 | 137 | 0.280 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 101 | 0.270 |
Why?
|
| Betacoronavirus | 2 | 2020 | 181 | 0.270 |
Why?
|
| Aged | 14 | 2021 | 15087 | 0.260 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 159 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 205 | 0.250 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2004 | 12 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 219 | 0.250 |
Why?
|
| Computer Simulation | 1 | 2009 | 486 | 0.240 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 464 | 0.240 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 336 | 0.230 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 178 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2023 | 714 | 0.220 |
Why?
|
| Pandemics | 2 | 2020 | 691 | 0.220 |
Why?
|
| Stents | 1 | 2009 | 500 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 552 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2004 | 17 | 0.210 |
Why?
|
| Retrospective Studies | 8 | 2021 | 6948 | 0.200 |
Why?
|
| Premedication | 1 | 2003 | 20 | 0.200 |
Why?
|
| Lactones | 1 | 2003 | 16 | 0.200 |
Why?
|
| Vena Cava, Inferior | 1 | 2004 | 34 | 0.200 |
Why?
|
| Pain | 2 | 2021 | 400 | 0.200 |
Why?
|
| Urinary Bladder Diseases | 1 | 2003 | 10 | 0.200 |
Why?
|
| Diverticulum | 1 | 2003 | 12 | 0.200 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 133 | 0.200 |
Why?
|
| Swine | 4 | 2012 | 397 | 0.190 |
Why?
|
| Lasers, Solid-State | 1 | 2022 | 19 | 0.180 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2022 | 20 | 0.180 |
Why?
|
| Feasibility Studies | 4 | 2019 | 593 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 202 | 0.180 |
Why?
|
| Iohexol | 2 | 2012 | 18 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2003 | 505 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2015 | 3328 | 0.180 |
Why?
|
| Nomograms | 1 | 2021 | 20 | 0.180 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Survival Rate | 2 | 2018 | 847 | 0.160 |
Why?
|
| Prognosis | 2 | 2021 | 1791 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 31 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2021 | 199 | 0.160 |
Why?
|
| Anastomosis, Surgical | 2 | 2012 | 118 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 20 | 0.150 |
Why?
|
| Recurrence | 1 | 2021 | 664 | 0.150 |
Why?
|
| Workload | 1 | 2020 | 133 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.150 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 120 | 0.150 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2019 | 14 | 0.140 |
Why?
|
| Pyelonephritis | 1 | 2019 | 8 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2020 | 888 | 0.140 |
Why?
|
| Equipment Design | 2 | 2010 | 373 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 92 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 41 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 372 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 102 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 484 | 0.130 |
Why?
|
| Kidney Transplantation | 2 | 2019 | 326 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 128 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 468 | 0.120 |
Why?
|
| Female | 10 | 2019 | 34298 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 530 | 0.120 |
Why?
|
| Intestinal Perforation | 1 | 2015 | 17 | 0.110 |
Why?
|
| Rectal Diseases | 1 | 2015 | 29 | 0.110 |
Why?
|
| Pelvis | 1 | 2015 | 64 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 88 | 0.110 |
Why?
|
| Cryosurgery | 2 | 2005 | 28 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 56 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5656 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2004 | 50 | 0.100 |
Why?
|
| Adult | 9 | 2019 | 17508 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 53 | 0.100 |
Why?
|
| Suture Techniques | 2 | 2012 | 97 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 213 | 0.100 |
Why?
|
| Time Factors | 4 | 2012 | 3777 | 0.090 |
Why?
|
| Renal Circulation | 1 | 2012 | 14 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 131 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2020 | 2113 | 0.080 |
Why?
|
| Sus scrofa | 1 | 2010 | 30 | 0.080 |
Why?
|
| Surgical Mesh | 1 | 2011 | 60 | 0.080 |
Why?
|
| Hernia, Inguinal | 1 | 2011 | 41 | 0.080 |
Why?
|
| Species Specificity | 1 | 2010 | 344 | 0.080 |
Why?
|
| Suction | 1 | 2009 | 34 | 0.070 |
Why?
|
| Urachus | 1 | 2008 | 3 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 644 | 0.070 |
Why?
|
| Animals | 5 | 2023 | 21450 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 46 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2009 | 222 | 0.070 |
Why?
|
| Risk Factors | 2 | 2020 | 5466 | 0.070 |
Why?
|
| Administration, Intravesical | 2 | 2020 | 14 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1042 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2496 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 2 | 2005 | 124 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2005 | 13 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 367 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2005 | 144 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 37 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 33 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1715 | 0.050 |
Why?
|
| Sulfones | 1 | 2003 | 43 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2003 | 992 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 344 | 0.050 |
Why?
|
| Diagnosis-Related Groups | 1 | 2003 | 86 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2005 | 142 | 0.050 |
Why?
|
| Cystadenoma | 1 | 2002 | 7 | 0.050 |
Why?
|
| Telephone | 1 | 2003 | 123 | 0.050 |
Why?
|
| Adenoma | 1 | 2003 | 70 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 70 | 0.050 |
Why?
|
| Watchful Waiting | 1 | 2022 | 33 | 0.050 |
Why?
|
| Kidney | 1 | 2005 | 458 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1573 | 0.050 |
Why?
|
| Equipment Failure | 2 | 2015 | 69 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2003 | 745 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 210 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 277 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 77 | 0.040 |
Why?
|
| Cell Movement | 1 | 2023 | 482 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2021 | 50 | 0.040 |
Why?
|
| Length of Stay | 2 | 2014 | 828 | 0.040 |
Why?
|
| Urologic Diseases | 1 | 2020 | 18 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2023 | 588 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 49 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2020 | 57 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 2639 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 700 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 170 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 521 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 377 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 987 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 710 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2003 | 802 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 741 | 0.030 |
Why?
|
| Incisional Hernia | 1 | 2015 | 15 | 0.030 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2015 | 15 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2015 | 52 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2015 | 63 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 376 | 0.030 |
Why?
|
| Operative Time | 1 | 2014 | 94 | 0.030 |
Why?
|
| United States | 2 | 2020 | 8166 | 0.030 |
Why?
|
| Learning | 1 | 2015 | 186 | 0.030 |
Why?
|
| Gallbladder | 1 | 2014 | 40 | 0.030 |
Why?
|
| Laparotomy | 1 | 2014 | 56 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2014 | 95 | 0.020 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 17 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2011 | 140 | 0.020 |
Why?
|
| Contraindications | 1 | 2011 | 52 | 0.020 |
Why?
|
| Cattle | 1 | 2011 | 320 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 579 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1432 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11172 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 432 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 874 | 0.020 |
Why?
|
| Renal Veins | 1 | 2008 | 8 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 37 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 30 | 0.020 |
Why?
|
| Urinary Diversion | 1 | 2006 | 12 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2008 | 178 | 0.020 |
Why?
|
| gamma Catenin | 1 | 2005 | 6 | 0.010 |
Why?
|
| Desmoplakins | 1 | 2005 | 10 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 2005 | 16 | 0.010 |
Why?
|
| Cadherins | 1 | 2005 | 90 | 0.010 |
Why?
|
| beta Catenin | 1 | 2005 | 100 | 0.010 |
Why?
|
| Seminoma | 1 | 2004 | 2 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 289 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 2004 | 35 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 149 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 611 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 216 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 204 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2003 | 3 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 321 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4855 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 663 | 0.010 |
Why?
|
| Emergencies | 1 | 2003 | 124 | 0.010 |
Why?
|
| Outpatients | 1 | 2003 | 143 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 200 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 1235 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 491 | 0.010 |
Why?
|
| Child | 1 | 2005 | 4633 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 1662 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 6349 | 0.010 |
Why?
|